Embracing artificial intelligence design for better radiopharmaceuticals  

作　　者：Jinping Tao Xiangxing Kong Zhi Yang Hua Zhu 

机构地区：[1]Department of Nuclear Medicine,Peking University Cancer Hospital&Institute,Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education/Beijing,Key Laboratory for Research and Evaluation of Radiopharmaceuticals,National Medical Products Administration,Beijing,China [2]School of Medicine,Guizhou University,Guiyang,China [3]Institute of Medical Technology,Peking University Health Science Center,Beijing,China [4]Department of Chemistry,Beijing University of Technology,Beijing,China

出　　处：《iRADIOLOGY》2024年第4期412-416,共5页融合影像学(英文)

基　　金：Capital's Funds for Health Improvement and Research,Grant/Award Numbers:2022‐2Z‐2154,2022‐2Z‐2155;Youth talent support program,Grant/Award Number:A002863。

摘　　要：1|INTRODUCTION Cancer has emerged as a significant threat to human life,and its incidence and mortality are increasing rapidly.As clinicians increasingly seek to noninvasively investigate tumor phenotypes and evaluate functional and molecular responses to therapy,the combination of diagnostic im-aging with targeted therapy is becoming more widely implemented[1].Targeted radionuclide therapy involves the use of small molecules,peptides,and/or antibodies as carriers for therapeutic radionuclides,with these being referred to as radiopharmaceuticals.Radiopharmaceuti-cals,also known as molecular probes in nuclear medicine,play a vital role in clinical diagnosis and therapy.Currently,there are numerous radiopharmaceuticals approved or under research worldwide for a wide range of indications.At the end of March 2022,there were 60 radiopharmaceuticals approved for marketing by the Food and Drug Administration(FDA)[2](Supplemental Table)[2].As of October 2023,42 radiopharmaceuticals have been approved for marketing by the National Medical Products Administration(NMPA)[3].However,there remains an urgent need to identify new targets and new drug molecules to advance the process of radiopharma-ceutical research and development.

关 键 词：artificial intelligence RADIOPHARMACEUTICALS nuclear medicine 

分 类 号：R73[医药卫生—肿瘤]